SCHEMBL4197150

SCHEMBL4197150

Cc1ccccc1CC(=O)c1c(O)c2cccnc2n(-c2cccc(OC(F)(F)F)c2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 2/20 0.41
PDE4D Q08499 2/20 0.41
IDO1 P14902 1/20 0.39
TOP2A P11388 1/20 0.38
HPD P32754 1/20 0.38
RECQL P46063 1/20 0.36
REN P00797 1/20 0.36
CHRM5 P08912 1/20 0.36
KCNH2 Q12809 1/20 0.36
SCN5A Q14524 1/20 0.36
SCN9A Q15858 1/20 0.36
KDM4E B2RXH2 2/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
MAPT P10636 2/20 0.36
PDE4A P27815 1/20 0.35
PDE4C Q08493 1/20 0.35
BCL2L1 Q07817 1/20 0.35
POLB P06746 2/20 0.35
TP53 P04637 1/20 0.35
CNR2 P34972 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4191918 0.91 PDE4B (0.41) PDE4BPDE4DIDO1TOP2AHPD
SCHEMBL4182610 0.90 ADORA2A (0.43) PDE4BPDE4DIDO1TOP2AKCNH2
SCHEMBL4194573 0.90 MAPT (0.41) PDE4BPDE4DIDO1TOP2ACHRM5
SCHEMBL4194572 0.90 PDE4B (0.41) PDE4BPDE4DIDO1TOP2AHPD
SCHEMBL4182715 0.88 TP53 (0.45) PDE4BPDE4DKDM4ESMN1; SMN2MAPT
SCHEMBL4187682 0.88 PDE4B (0.43) PDE4BPDE4DIDO1TOP2AHPD
SCHEMBL4192220 0.88 PDE4B (0.39) PDE4BPDE4DIDO1TOP2AHPD
SCHEMBL4185730 0.87 PDE4B (0.43) PDE4BPDE4DIDO1TOP2AKCNH2
SCHEMBL4194557 0.86 BCL2L1 (0.43) PDE4BPDE4DIDO1TOP2AKCNH2
SCHEMBL4188348 0.84 CNR2 (0.43) PDE4BPDE4DIDO1TOP2AKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1925617-B1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA PHARM CO LTD (JP) 2012-11-14 EP disclosed
US-8193356-B2 Heterocycle compound, and production process and application thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2012-06-05 US disclosed
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof ASKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-21 US disclosed
EP-1925617-A1 HETEROCYCLIC COMPOUND, AND PRODUCTION PROCESS AND USE THEREOF ASKA Pharmaceutical Co., Ltd. (JP) 2008-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131467-A1 Heterocycle Compound, and Production Process and Application Thereof PDE3B, PDE4B, PDE7A PDE4B 2/4885PDE4D 7/4885IDO1 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.